Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$25.70
▼ $0.11 (-0.4%)
Market data updated: 09/19 07:08 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$2.28B
Day Range
$25.61 - $27.10
52-Week Range
$15.96 - $34.72
Beta
—
Next Earnings
04.11.2026
Support
$17.92
Resistance
$27.50
ZLAB is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-22.1% (1Y)
Strengths: 18/30 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 38.5%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$3.27 vs. price $25.70 (-112.7%)
Fair Value
Signal tension
Growth scores strong (79/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
61
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
79
Quality
63
Value
38
Momentum
76
Risk
46
Sentiment
80
Fundamental
39
Institutional
25
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Zai Lab Limited has primarily focused on its stock performance and clinical developments. Analysts have examined whether its shares appear overvalued based on sales metrics, while comparisons with competitors like argenx SE (ARGX) highlighted its Phase 3 ALKIVIA study results for VYVGART Hytrulo in autoimmune myositis. Additionally, reports noted Zai Lab’s involvement in the expanding DLL3 targeted therapies market, projected to exceed $2 billion by 2030, alongside industry peers. Market fluctuations in its ADRs were also briefly mentioned.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Zai Lab Limited. News trend score: 80. Reason: 11 of the last 20 articles are positive, versus 6 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
32
🎯 Conviction (vs. Emotion)
43
Psychology
38
Fundamentals
39
Technical
76
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+41%
Market Narrative
58
Fundamental Reality
43
Narrative Gap
+15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ZLAB’s market behavior suggests a dominant *euphoria* state, driven by extreme positive sentiment and strong momentum relative to its 200-day average. The narrative gap (64 vs. 43) implies investors may be overestimating upside potential, while modest RSI (60) and peer underperformance hint at selective optimism. Herding is muted, and FOMO is present but secondary, indicating a cautious yet bullish bias. The key question: *Is this euphoria anchored in fundamentals, or will it collapse under peer drag?*
Updated: 09/09/2026, 09:54 AM
What could change this?
👥 What the crowd believes
"Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading"
"Global DLL3 targeted therapies market opportunity projected to exceed USD 2 billion by 2030"
"Zai Lab Limited and argenx SE announced positive topline results on August 17 from their Phase 3 ALKIVIA study"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 88/100
🔴 Weakest match
Jack Schwager — 38/100
🗣️ Why do they disagree?
ZLAB’s divergent scores reflect stark contrasts in how these methodologies weigh its potential. Walter Bagehot and Peter Lynch’s high scores (88 and 85) suggest strong liquidity and growth undervaluation, respectively—aligning with their focus on resilience and momentum-driven opportunities. Meanwhile, the lower scores from Graham (59), Livermore (58), and Veblen (56) indicate caution, as none of these frameworks find clear evidence of intrinsic value, defensive positioning, or sustainable profitability. The middle tier—Fisher (63), Housel (60), and even the Enterprising Investor Graham (44)—sits uneasily between optimism and skepticism, with Fisher dismissing it as merely ‘solid’ and Marks (38) flagging valuation risks. The lowest scores (Mackay’s 40, Marks’ 36) hint at crowd-driven hype or late-cycle warning signs, while the efficient-market camp (50) simply sees no compelling edge over passive investing. The debate hinges on whether ZLAB’s growth justifies its risks or if it’s a speculative bet with no clear edge.
Walter Bagehot
Lombard Street (1873)
🟢 88
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 85
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 67
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 63
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 60
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 59
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 54
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 50
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 47
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 43
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 43
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 42
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 38
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 1 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
58.6%
Operating Margin
-49.9%
Net Margin
-38.1%
EBITDA Margin
-46.6%
ROE
-24.5%
ROA
-15.0%
ROIC
—
EPS
-$0.16
Cash
$679.57M
Total Debt
$204.53M
Current Ratio
2.45
Debt/Equity
0.29
How is Fair Value calculated? →
Current Price
$25.70
Estimated Fair Value (DCF)
-$3.27
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-112.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-198.61M | $-182.21M |
| 2 | 19.4% | $-237.09M | $-199.56M |
| 3 | 13.8% | $-269.69M | $-208.25M |
| 4 | 8.1% | $-291.61M | $-206.58M |
| 5 | 2.5% | $-298.90M | $-194.26M |
Base FCF (last actual year)
$-158.89M
Terminal Value
$-4.71B
Present Value of Terminal Value
$-3.06B
Enterprise Value
$-4.05B
Net Debt
$-475.04M
Equity Value
$-3.58B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.65
Tangible Book Value per Share (Tangible NAV)
$0.58
Sentiment based on basic keywords (not AI) — 11 positive, 3 neutral, 6 negative out of the last 20 articles.
Yahoo · 14.9.2026
Benzinga · 10.9.2026
Yahoo · 6.9.2026
Simply Wall St. · 6.9.2026
Yahoo · 4.9.2026
MT Newswires · 4.9.2026
Yahoo · 2.9.2026
MT Newswires · 2.9.2026
Benzinga · 2.9.2026
Yahoo · 31.8.2026
MT Newswires · 31.8.2026
Yahoo · 28.8.2026
MT Newswires · 28.8.2026
Yahoo · 25.8.2026
MT Newswires · 25.8.2026
Yahoo · 20.8.2026
Insider Monkey · 20.8.2026
Yahoo · 20.8.2026
GlobeNewswire · 20.8.2026
Yahoo · 19.8.2026
Zai Lab Limited (ZLAB) currently has a StockIQ AI score of 61/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ZLAB currently scores 61/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ZLAB's estimated fair value is -$3.27, which is 112.7% below the current price of $25.70. This is one valuation model among several signals in the fair-value category, not a price target.
ZLAB's technical score is 76/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 38.5%; Free cash flow growth: 27.9%; Net income growth: 31.7%.
Based on the real signals StockIQ computed: Estimated fair value: -$3.27 vs. price $25.70 (-112.7%); Operating margin: -49.9% (negative); Net margin: -38.1% (negative).
StockIQ has no recorded dividend payment history for ZLAB.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 6 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Chen Yajing | Open Market Sale | 19.8.2026 | 260 | -260 | $27.00 |
| Chen Yajing | Exercise of Derivative Securities | 14.8.2026 | 1,250 | +1,250 | — |
| Chen Yajing | Exercise of Derivative Securities | 14.8.2026 | 1,250 | -1,250 | — |
| Chen Yajing | Tax Withholding in Shares | 14.8.2026 | 427 | -427 | $25.90 |
| Lis William | Open Market Sale | 12.8.2026 | 8,506 | -8,506 | $25.00 |
| Lis William | Open Market Sale | 12.8.2026 | 41,931 | -8,506 | $25.00 |
| Chen Yajing | Open Market Sale | 11.8.2026 | 619 | -619 | $25.00 |
| Chen Yajing | Open Market Sale | 11.8.2026 | 35,072 | -619 | $25.00 |
| Du Ying | Grant/Award from Employer | 2.7.2026 | 80,393 | +80,393 | — |
| Du Ying | Exercise of Derivative Securities | 2.7.2026 | 11,048 | +11,048 | — |
| Du Ying | Exercise of Derivative Securities | 2.7.2026 | 11,048 | -11,048 | — |
| Du Ying | Tax Withholding in Shares | 2.7.2026 | 4,348 | -4,348 | $19.12 |
| Du Ying | Exercise of Derivative Securities | 2.7.2026 | 1,225,749 | +11,048 | — |
| Du Ying | Tax Withholding in Shares | 2.7.2026 | 1,221,401 | -4,348 | $19.12 |
| Du Ying | Exercise of Derivative Securities | 2.7.2026 | 33,146 | -11,048 | — |
| Du Ying | Grant/Award from Employer | 2.7.2026 | 80,393 | +80,393 | — |
| GAYNOR RICHARD | Open Market Purchase | 1.7.2026 | 1,736 | +1,736 | $19.05 |
| Du Ying | Tax Withholding in Shares | 1.7.2026 | 7,083 | -7,083 | $19.15 |
| Du Ying | Exercise of Derivative Securities | 1.7.2026 | 18,000 | +18,000 | — |
| Du Ying | Exercise of Derivative Securities | 1.7.2026 | 18,000 | -18,000 | — |
| Du Ying | Exercise of Derivative Securities | 1.7.2026 | 1,221,784 | +18,000 | — |
| Du Ying | Tax Withholding in Shares | 1.7.2026 | 1,214,701 | -7,083 | $19.15 |
| Du Ying | Exercise of Derivative Securities | 1.7.2026 | 36,000 | -18,000 | — |
| GAYNOR RICHARD | Open Market Purchase | 1.7.2026 | 80,737 | +1,736 | $19.05 |
| Du Ying | Open Market Sale | 30.6.2026 | 7,026 | -7,026 | $18.53 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,017,185 shares short as of 2026-08-31 · vs. 6,534,451 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
59.7% of trading volume this week was short selling, vs. 82.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology